Abstract
Standard chemotherapy administered systemically has a limited efficacy in the treatment of brain tumors. One of the major obstacles in the treatment of brain neoplasias is the impediment to delivery across the intact blood-brain barrier (BBB). Many innovative approaches have been developed to circumvent this obstacle. One such strategy is BBB disruption (BBBD), which successfully increases the delivery of antineoplastic agents to the central nervous system (CNS). This chapter describes the application of the BBBD technique in rats. Different methods to evaluate and measure BBB permeability following hyperosmolar mannitol infusion including Evans blue staining, albumin immunohistochemistry, and dynamic magnetic resonance imaging are also described.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71:2585–2597
Holsi P, Sappino A P, de Tribolet N, Dietrich PY (1998) Malignant glioma: should chemotherapy be overthrown by experimental treatments ? Ann Oncol 6:589–600
Fortin D, Neuwelt EA (2002) Therapeutic manipulation of the blood-brain barrier. Neurobase-neurosurgery. First edition. Medlink CD-ROM
Kroll RA, Neuwelt EA (1998) Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 42:1083–1100
Rapoport SI, Hori M, Klatzo I (1972) Testing of a hypothesis for osmotic opening of the blood-brain barrier. Am J Physiol 223:323–331
Neuwelt EA (ed) (1989) Implications of the Blood-Brain Barrier and Its Manipulation. Vol 1 and 2. New York, Plenum
Pardridge WM (1991) Advances in cell biology of blood-brain barrier transport. Semin Cell Biol 2:419–426
Pardridge WM (2002) Targeting neurotherapeutic agents through the blood-brain barrier. Arch Neurol 59:35–40
Pardridge WM (1997) Drug delivery to the brain. J Cereb Blood Flow Metab 17:713–731
Bradbury MWB (1986) Appraisal of the role of endothelial cells and glia in barrier breakdown. In Suckling AJ, Rumsby MG, Bradbury MWB (eds): The Blood-Brain Barrier in Health and Disease. Chichester, Ellis Horwood, pp 128–129
Selman WR, Lust WD, Ratcheson RA (1996) Cerebral blood flow. In: RH Wilkins, Rengachary SS (eds): Neurosurgery. New York, McGraw-HILL, 1997–2007
Blanchette M, Pellerin M, Tremblay L, Lepage M, Fortin D (2009) Real time monitoring of Gd-DTPA during osmotic blood-brain barrier disruption using MRI in normal Wistar rats. Neurosurgery, accepted 30 march 2009
Bhattacharjee AK, Nagashima T, Kondoh T, Tamaki N (2001) Quantification of early blood-brain barrier disruption by in situ brain perfusion technique. Brain Res Prot 8:126–131
Rawson RA (1942) The binding of T-1824 and structurally related diazo dyes by the plasma proteins. Am J Physiol 138:708–717
Landis CS, Li X, Telang FW, Coderre JA, Micca PL, Rooney WD, Latour LL, Vétek G, Pályka I, Springer CS (2000) Determination of the MRI contrast agent concentration time course in vivo following bolus injection: effect of equilibrium transcytolemmal water exchange. Magn Reson Med 44: 563–574
Doolittle ND, Miner ME, Hall WA, Siegal T, Hanson EJ, Osztie E, McAllister LD, Bubalo JS, Kraemer DF, Fortin D, Nixon R, Muldoon LL, Neuwelt EA (2000) Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 88:637–647
Yang W, Barth RF, Carpenter DE, Moeschberger ML, Goodman JH (1996) Enhanced delivery of boronophenylalanine by means of intracarotid injection and blood-brain barrier disruption for neutron capture therapy. Neurosurgery 38:985–992
Kraemer DF, Fortin D, Doolittle ND, Neuwelt EA (2001) Association of total dose intensity of chemotherapy in primary central nervous system lymphoma and survival. Neurosurgery 48:1033–1041
Remsen LG, Pagel MA, McCormack CI, Fiamengo S, Sexton G, Neuwelt EA (1999) The influence of anesthetic choice, PaCO2, and other factors on osmotic blood brain barrier disruption in rats with brain tumor xenografts. Anesth Analg 88:559–567
Fortin D, McCormick CI, Remsen LG, Nixon R, Neuwelt EA (2000) Unexpected neurotoxicity of etoposide phosphate administered in combination with other chemotherapeutic agents after blood-brain barrier modification to enhance delivery, using propofol for general anesthesia, in a rat model. Neurosurgery 47:199–207
Gummerlock MK, Neuwelt EA (1990) The effects of anesthesia on osmotic blood-brain barrier disruption. Neurosurgery 26:268–277
Vorbrodt AW, Dobrogowska DH, Tarnawski M, Lossinsky AS (1994) A quantitative immunocytochemical study of the osmotic opening of the blood–brain barrier to endogenous albumin. J Neurocytol 23:792–800
Blasberg RG, Groothuis D, Molnar P (1990) A review of hyperosmotic blood-brain barrier disruption in seven experimental brain tumor models, in Johansson BB, Owman C, Widner H (eds): Pathophysiology of the Blood-Brain Barrier. Amsterdam, Elsevier, 197–220
Rapoport SI, Fredericks WR, Ohno K, Pettigrew KD (1980) Quantitative aspects of reversible osmotic opening of the blood-brain barrier. Am J Physiol 238:R421–R431
Doran SE, Ren XD, Betz AL, Pagel MA, Neuwelt EA, Roessler BJ, Davidson BL (1995) Gene expression from recombinant viral vectors in the CNS following blood-brain barrier disruption. Neurosurgery 36:965–970
Muldoon LL, Nilaver G, Kroll RA, Pagel MA, Breakefield XO, Chiocca EA, Davidson BL, Weissleder R, Neuwelt EA (1995) Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpes virus and iron oxide particles to normal rat brain. Am J Pathol 147:1840–1851
Neuwelt EA, Barnett PA, Hellström I, Hellström KE, Beaumier P, McCormick CI, Weigel RM (1988) Delivery of melanoma-associated immunoglobulin monoclonal antibody and Fab fragments to normal brain utilizing osmotic blood-brain barrier disruption. Cancer Res 48:4725–4729
Neuwelt EA, Specht HD, Barnett PA, Dahlborg SA, Miley A, Larson SM, Brown P, Eckerman KF, Hellström KE, Hellström I (1987) Increased delivery of tumor-specific monoclonal antibodies to brain after osmotic blood-brain barrier modification in patients with melanoma metastatic to the central nervous system. Neurosurgery 20:885–895
Neuwelt EA, Weissleder R, Nilaver G, Kroll RA, Roman-Goldstein S, Szumowski J, Pagel MA, Jones RS, Remsen LG, McCormick CI, et al. (1994) Delivery of virus-sized iron oxide particles to rodent CNS neurons. Neurosurgery 34:777–784
Nilaver G, Muldoon LL, Kroll RA, Pagel MA, Breakefield XO, Davidson BL, Neuwelt EA (1995) Delivery of herpes virus and adenovirus to nude rat intracerebral tumors following osmotic blood-brain barrier disruption. Proc Natl Acad Sci U S A 92:9829–9833
Freedman FB, Johnson JA (1969) Equilibrium and kinetic properties of the Evans blue–albumin system. Am J Physiol 216:675–681
Fortin D, Adams R, Gallez A (2004) A blood-brain barrier disruption model eliminating the hemodynamic effect of ketamine. Can J Neurol Sci 31:248–53
Acknowledgments
This work was supported by a grant from the CIHR (DF), as well as the National Bank of Canada Research Chair on Brain Tumor treatment (DF).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Blanchette, M., Fortin, D. (2011). Blood-Brain Barrier Disruption in the Treatment of Brain Tumors. In: Nag, S. (eds) The Blood-Brain and Other Neural Barriers. Methods in Molecular Biology, vol 686. Humana Press. https://doi.org/10.1007/978-1-60761-938-3_23
Download citation
DOI: https://doi.org/10.1007/978-1-60761-938-3_23
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60761-937-6
Online ISBN: 978-1-60761-938-3
eBook Packages: Springer Protocols